Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
WETH
Wetouch Technology Inc.
Medical applications revenue suggests involvement as a component provider in medical devices, i.e., Medical Device Components.
|
$20.28M |
$1.89
+10.88%
|
|
IRIX
IRIDEX Corporation
IRIDEX directly designs, manufactures and sells ophthalmology devices (laser platforms, delivery systems) for eye diseases.
|
$19.54M |
$1.18
-0.84%
|
|
FEMY
Femasys Inc.
Femasys manufactures medical devices and biometrics for women's reproductive health (FemBloc, FemaSeed, FemVue, etc.).
|
$19.36M |
$0.59
+0.49%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$19.30M |
$6.07
-4.64%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$18.63M |
$8.62
-1.54%
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$18.25M |
$0.88
-8.87%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$18.15M |
$1.96
+2.89%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$18.04M |
$2.00
-2.91%
|
|
DSY
Big Tree Cloud Holdings Limited
Provides OEM/ODM manufacturing services, i.e., contract manufacturing for others.
|
$17.15M |
$0.30
+0.23%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
LB-100 is Lixte's lead oncology drug candidate (PP2A inhibitor) being developed for cancer therapy, constituting the primary product/offerable asset.
|
$17.11M |
$3.65
-2.80%
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$17.10M |
$1.17
-1.68%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$17.07M |
$10.98
+0.32%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$17.06M |
$1.07
+0.47%
|
|
PFHO
Pacific Health Care Organization, Inc.
PFHO provides workers' compensation cost containment services, including healthcare provider network access and case management, within the healthcare services ecosystem.
|
$16.90M |
$1.30
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$16.84M |
$1.46
+1.39%
|
|
UEEC
United Health Products, Inc.
CelluSTAT is a surgical hemostatic device used in operative settings, categorizing the company as a Surgical Equipment manufacturer.
|
$16.81M |
$0.05
|
|
COSM
Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
|
$16.61M |
$0.55
+6.04%
|
|
LESL
Leslie's, Inc.
AccuBlue water-testing systems and related diagnostic testing capabilities are direct testing instruments offered to customers.
|
$16.52M |
$1.81
+1.97%
|
|
MDXH
MDxHealth S.A.
MDxHealth's portfolio includes liquid-based diagnostic tests (Select mdx, Resolve mdx, ExoDx) that fit the Liquid Biopsy category.
|
$16.19M |
$3.27
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$16.13M |
$8.15
+3.43%
|
|
KNW
Know Labs, Inc.
Core product: KnowU CGM wearable and glucose monitoring device.
|
$16.05M |
$2.14
|
|
TOMZ
TOMI Environmental Solutions, Inc.
Product category aligns with healthcare-themed medical devices and equipment, including disinfection hardware (SteraMist SIS/CES).
|
$15.90M |
$0.78
-2.17%
|
|
NXPL
NextPlat Corp
Management is pivoting toward higher-margin healthcare services and 340B contracts, a Healthcare Services & Facilities focus.
|
$15.86M |
$0.61
+0.65%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$15.31M |
$0.89
-1.67%
|
|
RBOT
Vicarious Surgical Inc.
The company directly manufactures and sells surgical equipment in a robotic system for minimally invasive surgery.
|
$15.30M |
$2.65
+3.31%
|
|
MRM
MEDIROM Healthcare Technologies Inc.
MOTHER Bracelet and related biometric sensing capabilities align with Medical Devices & Biometrics.
|
$15.25M |
$1.92
-0.52%
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$15.12M |
$1.31
+0.38%
|
|
ADGM
Adagio Medical Holdings, Inc.
ADGM is a medical technology company whose core offerings are medical devices/biometrics for cardiac ablation.
|
$14.92M |
$0.89
-6.70%
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$14.65M |
$0.34
-0.99%
|
|
COCH
Envoy Medical, Inc.
Envoy Medical designs and manufactures implantable medical devices with biometric sensing capabilities (Acclaim CI and Esteem FI-AMEI).
|
$14.63M |
$0.66
-5.01%
|
|
PETV
PetVivo Holdings, Inc.
PetVivo's Spryng is a veterinarian-administered medical device/biomaterial for osteoarthritis in dogs and horses.
|
$14.61M |
$1.15
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$14.59M |
$0.69
-0.72%
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$14.50M |
$0.57
-0.18%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-ALZ targets Alzheimer's disease, supporting Alzheimer's disease therapeutics as a focus area.
|
$14.45M |
$1.09
|
Showing page 32 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
